Top Health Care companies in Switzerland by Net Income Margin

This ranking features the top 33 Health Care companies in Switzerland ranked by Net Income Margin, averaging a Net Income Margin of -367.65%, for January 15, 2025.

Switzerland

Health Care

#	Name	Net Income Margin	Reported Date	Stock Price	Change	Country
1	Santhera Pharmaceuticals Holding AG 1 SANN.SW	52.97%	Dec. 31, 2023	USD 14.50	8.00%	Switzerland
2	Novartis AG 2 NOVN.SW	31.83%	Dec. 31, 2023	USD 98.71	-0.26%	Switzerland
3	Dottikon Es Holding AG 3 DESN.SW	24.71%	March 31, 2024	USD 229.49	0.50%	Switzerland
4	Bachem Holding AG 4 BANB.SW	19.38%	Dec. 31, 2023	USD 61.01	0.32%	Switzerland
5	Roche Holding AG 5 RO.SW	19.02%	Dec. 31, 2023	USD 310.22	0.71%	Switzerland
6	Ypsomed Holding AG 6 YPSN.SW	14.29%	March 31, 2024	USD 355.46	-1.48%	Switzerland
7	CPH Chemie + Papier Holding AG 7 CPHN.SW	12.64%	Dec. 31, 2023	USD 85.22	-0.53%	Switzerland
8	Tecan Group AG 8 TECN.SW	12.29%	Dec. 31, 2023	USD 244.50	0.95%	Switzerland
9	IVF Hartmann Holding AG 9 VBSN.SW	10.24%	Dec. 31, 2023	USD 165.41	0.50%	Switzerland
10	Straumann Holding AG 10 STMN.SW	10.20%	Dec. 31, 2023	USD 129.81	2.09%	Switzerland
11	Lonza Group AG 11 LONN.SW	9.74%	Dec. 31, 2023	USD 588.68	-0.80%	Switzerland
12	Medacta Group SA 12 MOVE.SW	9.27%	Dec. 31, 2023	USD 119.40	0.87%	Switzerland
13	Siegfried Holding AG 13 SFZN.SW	8.87%	Dec. 31, 2023	USD 1.04 K	-2.38%	Switzerland
14	DocMorris AG 14 0RRB.L	8.49%	Dec. 31, 2023	USD 19.40	2.88%	Switzerland
15	SKAN Group AG 15 SKAN.SW	8.22%	Dec. 31, 2023	USD 81.72	-0.97%	Switzerland
16	Basilea Pharmaceutica AG 16 BSLN.SW	6.63%	Dec. 31, 2023	USD 44.53	-0.85%	Switzerland
17	Ascom Holding AG 17 ASCN.SW	5.85%	Dec. 31, 2023	USD 4.52	-0.71%	Switzerland
18	COLTENE Holding AG 18 CLTN.SW	4.92%	Dec. 31, 2023	USD 56.52	-0.28%	Switzerland
19	Galenica AG 19 GALE.SW	4.63%	Dec. 31, 2023	USD 84.29	1.29%	Switzerland
20	Metall Zug AG 20 METN.SW	4.49%	Dec. 31, 2023	USD 1.16 K	0.97%	Switzerland
21	Sandoz Group AG 21 SDZ.SW	0.77%	Dec. 31, 2023	USD 42.16	0.08%	Switzerland
22	Medartis Holding AG 22 MED.SW	0.29%	Dec. 31, 2023	USD 73.39	4.71%	Switzerland
23	medmix AG 23 MEDX.SW	0.06%	Dec. 31, 2023	USD 11.09	-3.14%	Switzerland
24	Aevis Victoria SA 24 AEVS.SW	-4.30%	Dec. 31, 2023	USD 14.90	-4.42%	Switzerland
25	DSM-Firmenich AG 25 DSFIR.AS	-6.14%	Dec. 31, 2023	USD 97.52	0.29%	Switzerland
26	PolyPeptide Group AG 26 PPGN.SW	-16.06%	Dec. 31, 2023	USD 27.99	-3.47%	Switzerland
27	Kuros Biosciences AG 27 KURN.SW	-40.90%	Dec. 31, 2023	USD 24.15	-4.07%	Switzerland
28	CRISPR Therapeutics AG 28 CRSP	-41.38%	Dec. 31, 2023	USD 38.36	-1.26%	Switzerland
29	ADC Therapeutics SA 29 ADCT	-345.11%	Dec. 31, 2023	USD 1.71	-0.58%	Switzerland
30	AC Immune SA 30 ACIU	-366.41%	Dec. 31, 2023	USD 2.61	NA	Switzerland
31	Addex Therapeutics Ltd 31 ADXN	-654.47%	Dec. 31, 2023	USD 7.39	-3.40%	Switzerland
32	Molecular Partners AG 32 MOLN.SW	-880.70%	Dec. 31, 2023	USD 5.48	3.60%	Switzerland
33	Oculis Holding AG 33 OCS	-10,056.85%	Dec. 31, 2023	USD 22.44	0.27%	Switzerland

Frequently Asked Questions

Which Health Care company in Switzerland has the highest Net Income Margin ?

The Health Care company in Switzerland with the highest Net Income Margin is Santhera Pharmaceuticals Holding AG (Swiss Stock Exchange: SANN.SW) at 52.97%.
Which Health Care company in Switzerland has the lowest Net Income Margin ?

The Health Care company in Switzerland with the lowest Net Income Margin is Oculis Holding AG (NasdaqGM: OCS) at -10,056.85%.

What are the top 10 Health Care companies in Switzerland by Net Income Margin ?

The top 10 Health Care companies in Switzerland by Net Income Margin are Santhera Pharmaceuticals Holding AG, Novartis AG, Dottikon Es Holding AG, Bachem Holding AG, Roche Holding AG, Ypsomed Holding AG, CPH Chemie + Papier Holding AG, Tecan Group AG, IVF Hartmann Holding AG and Straumann Holding AG.
What are the bottom 10 Health Care companies in Switzerland by Net Income Margin ?

The bottom 10 Health Care companies in Switzerland by Net Income Margin are Oculis Holding AG, Molecular Partners AG, Addex Therapeutics Ltd, AC Immune SA, ADC Therapeutics SA, CRISPR Therapeutics AG, Kuros Biosciences AG, PolyPeptide Group AG, DSM-Firmenich AG and Aevis Victoria SA.